NSETrading Window30 Jun 2026 · 30 Jun 2026, 04:14 pm

Trading Window

Natco Pharma Limited · NATCOPHARM

✦ AI Summary

Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company will remain closed for Directors, Designated Persons, their immediate relatives, and all other connected persons from July 1, 2026, to 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Attachments (1)

📄

NATCOPHARM_30062026161354_Trading_Window_ClosureSE_Intimation.pdf

pdf

Download →
View document text
June 30, 2026 M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Closure of Trading Window We wish to inform you that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, with effect from July 1, 2026 to till 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ending June 30, 2026. The date of the Board Meeting for declaration of the unaudited financial results of the Company for the quarter ending June 30, 2026 will be intimated in due course of time. Thanking you Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer